Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Frontline FLAG-Ida for high-risk AML: data from the UK NCRI AML17 trial

Alan Burnett • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Clofarabine Daunorubicin
AML17

“The UK NCRI AML17 trial (ISRCTN55675535) investigated a number of interventions for younger patients with acute myeloid leukemia (AML). We spoke to Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, about the results of the comparison of FLAG-Ida and daunorubicin with clofarabine for high-risk AML in the trial, which were recently published. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

https://www.ncbi.nlm.nih.gov/pubmed/29875430”

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Alan Burnett

ISAL session highlights: gemtuzumab & small molecule inhibitors with chemotherapy in AML and APL
2:32
ISAL session highlights: gemtuzumab & small molecule inhibitors with chemotherapy in AML and APL
Alan Burnett • 21 Mar 2023
Standard treatment of elderly patients with AML & evaluating IDH inhibitors in younger patients
3:14
Standard treatment of elderly patients with AML & evaluating IDH inhibitors in younger patients
Alan Burnett • 21 Mar 2023
The future treatment of acute leukemias: part I
11:06
The future treatment of acute leukemias: part I
Alan Burnett et al. • 18 Jun 2019
The future treatment of acute leukemias: part II
19:48
The future treatment of acute leukemias: part II
Alan Burnett et al. • 18 Jun 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals